Zerdeçalın Genel Sağlık Üzerine Etkileri

Year 2021, Volume: 4 Issue: 2, 76 - 87, 06.09.2021

Cahit Erkul , Aliye Özenoğlu , Elif Reis

https://doi.org/10.51536/tusbad.950788

Cited By: 2

Abstract

Bitkisel ürünler insanlık tarihi boyunca çeşitli amaçlarla kullanılmıştır. Bu ürünlerin çoğu, ilaçların keşfi ve tasarımında yararlanılabilecek farmakolojik veya biyolojik aktiviteye sahiptir. Zerdeçal, zencefil ailesinin bir üyesi Kurkuma longa bitkisinden elde edilmiştir. Zerdeçal, Hint ayurvedik tıbbında ve Unani geleneksel tıbbında en az 2500 yıldır sindirim ve karaciğer hastalıkları, deri enfeksiyonları ve artrit tedavisinde kullanılmaktadır. İlk kez 1815'te Vogel ve Pelletier tarafından zerdeçaldan izole edilmiş olan kürküminin 1870'de saf ve kristal formu, 1910'da ise diferuloilmetan yapısı bulunmuştur. Zerdeçalın 100 gramında; 390 kcal, toplam 10 g yağ, 3 g doymuş yağ, 0 mg kolesterol, 0.2 g kalsiyum, 0.26 g fosfor, 10 mg sodyum, 2500 mg potasyum, 47.5 mg demir, 0.9 mg tiamin, 0.19 mg riboflavin, 4.8 mg niasin, 50 mg askorbik asit, toplam 69.9 g karbonhidrat, 21 g diyet lifi, 3 g şeker ve 8 g protein bulunmaktadır. Zerdeçaldaki ana biyoaktif bileşen olan kürkümin, antioksidan, anti-inflamatuar, anti-bakteriyel ve anti-aterosklerotik özelliklere sahiptir. Bu özellikleri zerdeçalı, Alzheimer, kanser, kardiyovasküler hastalıklar, diyabet, obezite ve depresyon gibi pek çok hastalığın tedavisinde ilgi çekici kılmıştır. Bu derlemede zerdeçalın genel sağlık üzerine etkilerinin irdelenmesi amaçlanmıştır.

Keywords

Zerdeçal, sağlık, inflamasyon, antioksidan, beslenme

Supporting Institution

Yoktur

Project Number

Herhangi bir projeden türetilmemiştir.

Thanks

Yoktur

The Effects of Turmeric on Overall Health

Abstract

Herbal products have been used for various purposes throughout human history. Many of these products have pharmacological or biological activity that can be utilized in the discovery and design of drugs. Turmeric is derived from the Curcuma longa plant, a member of the ginger family. Turmeric has been used in Indian Ayurvedic medicine and Unani traditional medicine for at least 2500 years to treat digestive and liver diseases, skin infections and arthritis. Curcumin, which was first isolated from turmeric by Vogel and Pelletier in 1815, was found in its pure and crystalline form in 1870 and its diferuloylmethane structure in 1910. In 100 grams of turmeric; 390 kcal, 10 g total fat, 3 g saturated fat, 0 mg cholesterol, 0.2 g calcium, 0.26 g phosphorus, 10 mg sodium, 2500 mg potassium, 47.5 mg iron, 0.9 mg thiamine, 0.19 mg riboflavin, 4.8 mg niacin, 50 mg ascorbic acid, a total of 69.9 g carbohydrates, 21 g dietary fiber, 3 g sugar and 8 g protein. Curcumin, the main bioactive ingredient in turmeric, has antioxidant, anti-inflammatory, anti-bacterial and anti-atherosclerotic properties. These properties have made turmeric interesting in the treatment of many diseases such as Alzheimer's, cancer, cardiovascular diseases, diabetes, obesity and depression. In this review, it is aimed to examine the effects of turmeric on general health.

Keywords

Antioxidants, Inflammation, Curcumin, Health

Project Number

Herhangi bir projeden türetilmemiştir.

References

• 1. Kocaadam B, Şanlier N. Curcumin, an active component of turmeric (Curcuma longa), and its effects on health. Crit Rev Food Sci Nutr. 2017;57(13):2889-2895. doi: 10.1080/10408398.2015.1077195.
• 2. Gupta SC, Sung B, Kim JH, Prasad S, Li S, Aggarwal BB. Multitargeting by turmeric, the golden spice: From kitchen to clinic. Mol Nutr Food Res. 2013;57(9):1510-28. doi: 10.1002/mnfr.201100741.
• 3. Kalkan İ. Zerdeçal (Hint Safranı) ve Sağlık. İçinde M.Tayfur(Ed.), Beslenme ve Diyetetik Güncel Konular-5,Alp Ofset Matbaacılık Ltd. Şti., Ankara, 1. Baskı, Türkiye 2018. ss.193-204.
• 4. Johnson RL, Foster S, Dog TL, Kiefer D. Zerdeçal (Curcuma longa). İçinde B.H..Sebeer(Ed.), National Geographic Şifalı Bitkiler Ansiklopedisi, Promat Basım Yayın Sanayi ve Tic. A.Ş., İstanbul,1.Baskı, Türkiye 2016. ss.183-185.
• 5. Chamoli RP, Bahuguna G. Turmeric (Curcuma Longa): From ancient medicine to current potential therapeutic agent as curcumin. Sci Cult. 2019;85:93-99.
• 6. Deogade S, Ghate S. Curcumin: Therapeutic applications in systemic and oral health. Int J Biol Pharm Res. 2015;6(4):281–290.
• 7. Morales I, Cerda-Troncoso C, Andrade V, Maccioni RB. The natural product curcumin as a potential coadjuvant in alzheimer's treatment. J Alzheimers Dis. 2017;60(2):451-460. doi: 10.3233/JAD-170354.
• 8. Rane JS, Bhaumik P, Panda D. Curcumin inhibits tau aggregation and disintegrates preformed tau filaments in vitro. J Alzheimers Dis. 2017;60(3):999-1014. doi: 10.3233/JAD-170351.
• 9. Fan CD, Li Y, Fu XT, Wu QJ, Hou YJ, Yang MF, Sun JY, Fu XY, Zheng ZC, Sun BL. Reversal of beta-amyloid-ınduced neurotoxicity in pc12 cells by curcumin, the important role of ros-mediated signaling and erk pathway. Cell Mol Neurobiol. 2017;37(2):211-222. doi: 10.1007/s10571-016-0362-3.
• 10. Marizzoni M, Cattaneo A, Mirabelli P, Festari C, Lopizzo N, Nicolosi V, Mombelli E, Mazzelli M, Luongo D, Naviglio D, Coppola L, Salvatore M, Frisoni GB. Short-Chain fatty acids and lipopolysaccharide as mediators between gut dysbiosis and amyloid pathology in alzheimer's disease. J Alzheimers Dis. 2020;78(2):683-697. doi: 10.3233/JAD-200306.
• 11. Zam W. Gut Microbiota as a Prospective Therapeutic Target for Curcumin: A review of mutual influence. J Nutr Metab. 2018;2018:1367984. doi: 10.1155/2018/1367984.
• 12. Mollazadeh H, Cicero AFG, Blesso CN, Pirro M, Majeed M, Sahebkar A. Immune modulation by curcumin: The role of interleukin-10. Crit Rev Food Sci Nutr. 2019;59(1):89-101. doi: 10.1080/10408398.2017.1358139.
• 13. Zheng K, Dai X, Xiao N, Wu X, Wei Z, Fang W, Zhu Y, Zhang J, Chen X. Curcumin ameliorates memory decline via inhibiting BACE1 expression and β-Amyloid pathology in 5×FAD transgenic mice. Mol Neurobiol. 2017;54(3):1967-1977. doi: 10.1007/s12035-016-9802-9.
• 14. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2•7 million participants. Lancet. 2011;378(9785):31-40. doi: 10.1016/S0140-6736(11)60679-X.
• 15. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4-14. doi: 10.1016/j.diabres.2009.10.007.
• 16. Jiménez-Osorio AS, Monroy A, Alavez S. Curcumin and insulin resistance-Molecular targets and clinical evidences. Biofactors. 2016;42(6):561-580. doi: 10.1002/biof.1302.
• 17. Kim HS, Hwang YC, Koo SH, Park KS, Lee MS, Kim KW, Lee MK. PPAR-γ activation increases insulin secretion through the up-regulation of the free fatty acid receptor GPR40 in pancreatic β-cells. PLoS One. 2013;8(1):e50128. doi: 10.1371/journal.pone.0050128.
• 18. Na LX, Li Y, Pan HZ, Zhou XL, Sun DJ, Meng M, Li XX, Sun CH. Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial. Mol Nutr Food Res. 2013;57(9):1569-77. doi: 10.1002/mnfr.201200131.
• 19. Hodaei H, Adibian M, Nikpayam O, Hedayati M, Sohrab G. The effect of curcumin supplementation on anthropometric indices, insulin resistance and oxidative stress in patients with type 2 diabetes: a randomized, double-blind clinical trial. Diabetol Metab Syndr. 2019;11:41. doi: 10.1186/s13098-019-0437-7.
• 20. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, Finkelstein EA, Hong Y, Johnston SC, Khera A, Lloyd-Jones DM, Nelson SA, Nichol G, Orenstein D, Wilson PW, Woo YJ. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123(8):933-44. doi: 10.1161/CIR.0b013e31820a55f5.
• 21. Li H, Sureda A, Devkota HP, Pittalà V, Barreca D, Silva AS, Tewari D, Xu S, Nabavi SM. Curcumin, the golden spice in treating cardiovascular diseases. Biotechnol Adv. 2020;38:107343. doi: 10.1016/j.biotechadv.2019.01.010.
• 22. Xu S, Kamato D, Little PJ, Nakagawa S, Pelisek J, Jin ZG. Targeting epigenetics and non-coding RNAs in atherosclerosis: from mechanisms to therapeutics. Pharmacol Ther. 2019;196:15-43. doi: 10.1016/j.pharmthera.2018.11.003.
• 23. Fraccarollo D, Galuppo P, Bauersachs J. Novel therapeutic approaches to post-infarction remodelling. Cardiovasc Res. 2012;94(2):293-303. doi: 10.1093/cvr/cvs109.
• 24. Lan C, Chen X, Zhang Y, Wang W, Wang WE, Liu Y, Cai Y, Ren H, Zheng S, Zhou L, Zeng C. Curcumin prevents strokes in stroke-prone spontaneously hypertensive rats by improving vascular endothelial function. BMC Cardiovasc Disord. 2018;18(1):43. doi: 10.1186/s12872-018-0768-6.
• 25. Xie CJ, Gu AP, Cai J, Wu Y, Chen RC. Curcumin protects neural cells against ischemic injury in N2a cells and mouse brain with ischemic stroke. Brain Behav. 2018;8(2):e00921. doi: 10.1002/brb3.921.
• 26. Lu Z, Liu Y, Shi Y, Shi X, Wang X, Xu C, Zhao H, Dong Q. Curcumin protects cortical neurons against oxygen and glucose deprivation/reoxygenation injury through flotillin-1 and extracellular signal-regulated kinase1/2 pathway. Biochem Biophys Res Commun. 2018;496(2):515-522. doi: 10.1016/j.bbrc.2018.01.089.
• 27. Sunagawa Y, Morimoto T, Wada H, Takaya T, Katanasaka Y, Kawamura T, Yanagi S, Marui A, Sakata R, Shimatsu A, Kimura T, Kakeya H, Fujita M, Hasegawa, K. A natural p300specific histone acetyltransferase inhibitor, curcumin, in addition to angiotensin-converting enzyme inhibitor, exerts beneficial effects on left ventricular systolic function after myocardial infarction in rats. Circ J. 2011;75(9):2151-2159.
• 28. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012;307(5):491-497. doi: 10.1001/jama.2012.39.
• 29. Zhao L, Lee JY, Hwang DH. Inhibition of pattern recognition receptor-mediated inflammation by bioactive phytochemicals. Nutr Rev. 2011;69(6):310-20. doi: 10.1111/j.1753-4887.2011.00394.x.
• 30. Magesh S, Chen Y, Hu L. Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents. Med Res Rev. 2012;32(4):687-726. doi: 10.1002/med.21257.
• 31. Jazayeri-Tehrani SA, Rezayat SM, Mansouri S, Qorbani M, Alavian SM, Daneshi-Maskooni M, Hosseinzadeh-Attar MJ. Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial. Nutr Metab (Lond). 2019;16:8. doi: 10.1186/s12986-019-0331-1.
• 32. Chuengsamarn S, Rattanamongkolgul S, Phonrat B, Tungtrongchitr R, Jirawatnotai S. Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial. J Nutr Biochem. 2014;25(2):144-150. doi: 10.1016/j.jnutbio.2013.09.013.
• 33. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30. doi: 10.3322/caac.21442.
• 34. Tuorkey MJ. Curcumin a potent cancer preventive agent: Mechanisms of cancer cell killing. Interv Med Appl Sci. 2014;6,139–146.
• 35. Ashour AA, Abdel-Aziz AA, Mansour AM, Alpay SN, Huo L, Ozpolat B. Targeting elongation factor-2 kinase (eEF-2K) induces apoptosis in human pancreatic cancer cells. Apoptosis. 2014;19(1):241-258. doi: 10.1007/s10495-013-0927-2.
• 36. Lee WH, Loo CY, Young PM, Traini D, Mason RS, Rohanizadeh R. Recent advances in curcumin nanoformulation for cancer therapy. Expert Opin Drug Deliv. 2014;11(8):1183-1201. doi: 10.1517/17425247.2014.916686.
• 37. Cheng MA, Chou FJ, Wang K, Yang R, Ding J, Zhang Q, Li G, Yeh S, Xu D, Chang C. Androgen receptor (AR) degradation enhancer ASC-J9® in an FDA-approved formulated solution suppresses castration resistant prostate cancer cell growth. Cancer Lett. 2018;417:182-191. doi: 10.1016/j.canlet.2017.11.038.
• 38. Nautiyal J, Banerjee S, Kanwar SS, Yu Y, Patel BB, Sarkar FH, Majumdar AP. Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells. Int J Cancer. 2011;128(4):951-961. doi: 10.1002/ijc.25410.
• 39. Mudduluru G, George-William JN, Muppala S, Asangani IA, Kumarswamy R, Nelson LD, Allgayer H. Curcumin regulates miR-21 expression and inhibits invasion and metastasis in colorectal cancer. Biosci Rep. 2011;31(3):185-197. doi: 10.1042/BSR20100065.
• 40. Hejazi J, Rastmanesh R, Taleban FA, Molana SH, Hejazi E, Ehtejab G, Hara N. Effect of curcumin supplementation during radiotherapy on oxidative status of patients with prostate cancer: A double blinded, randomized, placebo-controlled study. Nutr Cancer. 2016;68(1):77-85. doi: 10.1080/01635581.2016.1115527. 41. He ZY, Shi CB, Wen H, Li FL, Wang BL, Wang J. Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin. Cancer Invest. 2011;29(3):208-213. doi: 10.3109/07357907.2010.550592.
• 42. Friedrich MJ. Depression Is the leading cause of disability around the world. JAMA. 2017;317(15):1517. doi: 10.1001/jama.2017.3826.
• 43. Biswas SK. Does the Interdependence between oxidative stress and inflammation explain the antioxidant paradox?. Oxid Med Cell Longev. 2016;2016:5698931. doi: 10.1155/2016/5698931.
• 44. Laveti D, Kumar M, Hemalatha R, Sistla R, Naidu VG, Talla V, Verma V, Kaur N, Nagpal R. Anti-inflammatory treatments for chronic diseases: a review. Inflamm Allergy Drug Targets. 2013;12(5):349-361. doi: 10.2174/18715281113129990053.
• 45. Bergman J, Miodownik C, Bersudsky Y, Sokolik S, Lerner PP, Kreinin A, Polakiewicz J, Lerner V. Curcumin as an add-on to antidepressive treatment: a randomized, double-blind, placebo-controlled, pilot clinical study. Clin Neuropharmacol. 2013;36(3):73-77. doi: 10.1097/WNF.0b013e31828ef969.
• 46. Karaman BE, Köseler E. Zerdeçalın kronik hastalıklarla ilişkisi. Başkent Üniv Sağlık Bilim Fak Derg. 2017;2(2): 96-112.